Related references
Note: Only part of the references are listed.Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019
Le Wang et al.
FRONTIERS IN PUBLIC HEALTH (2022)
Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
Caroline E. Nunes-Xavier et al.
FRONTIERS IN ONCOLOGY (2022)
Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies
Jian-Xuan Sun et al.
FRONTIERS IN ONCOLOGY (2022)
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
Mari Karimaa et al.
MOLECULAR CANCER THERAPEUTICS (2022)
A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer
Krishna B. Singh et al.
ONCOGENE (2021)
Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer A Systematic Review and Network Meta-analysis
Lin Wang et al.
JAMA ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Amy C. Mandigo et al.
CANCER DISCOVERY (2021)
Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort
Adam B. Weiner et al.
JOURNAL OF UROLOGY (2020)
Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review
Kim Edmunds et al.
SUPPORTIVE CARE IN CANCER (2020)
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
Rodolfo Montironi et al.
CELLS (2020)
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
E. David Crawford et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy
Gergana E. Stoykova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Metabolic Disorders and Male Hypogonadotropic Hypogonadism
Rosario Pivonello et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Metabolic changes in patients with prostate cancer during androgen deprivation therapy
Koji Mitsuzuka et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Jingjing Chen et al.
NATURE GENETICS (2018)
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Ming Chen et al.
NATURE GENETICS (2018)
Hypogonadism Makes Dyslipidemia in Klinefelter's Syndrome
Hyo Serk Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2017)
A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management
Mathis Grossmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2016)
Androgen control of lipid metabolism in prostate cancer: novel insights and future applications
Lisa M. Butler et al.
ENDOCRINE-RELATED CANCER (2016)
p53 as a Regulator of Lipid Metabolism in Cancer
Alejandro Parrales et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Metabolic effects of androgen deprivation therapy
See Min Choi et al.
KOREAN JOURNAL OF UROLOGY (2015)
Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer
Zhe Zhang et al.
CANCER RESEARCH (2014)
Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness
Shuhua Yue et al.
CELL METABOLISM (2014)
Lipogenesis in cancer progression (Review)
Catherine Mounier et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
The fatty acid synthase inhibitor triclosan: repurposing an antimicrobial agent for targeting prostate cancer
Martin C. Sadowski et al.
ONCOTARGET (2014)
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2013)
Obesity and Prostate Cancer: Weighing the Evidence
Emma H. Allott et al.
EUROPEAN UROLOGY (2013)
Experience with degarelix in the treatment of prostate cancer
Neal D. Shore
THERAPEUTIC ADVANCES IN UROLOGY (2013)
Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study
Gideon Sartorius et al.
CLINICAL ENDOCRINOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Connecting the Lines between Hypogonadism and Atherosclerosis
Akl C. Fahed et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2012)
Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
Nancy B. Kuemmerle et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone
Steven A. Kaplan et al.
AGING MALE (2010)
Emerging cardiometabolic complications of androgen deprivation therapy
Karen Choong et al.
AGING MALE (2010)
Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men
Frederick C. W. Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones
Jie Hu et al.
NUTRITION & METABOLISM (2010)
The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis
Farhana Haseen et al.
JOURNAL OF CANCER SURVIVORSHIP (2010)
Association between lipid profile and circulating concentrations of estrogens in young men
Maciej Tomaszewski et al.
ATHEROSCLEROSIS (2009)
Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity
Dheeraj Kapoor et al.
DIABETES CARE (2007)
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias
Maisa Yoshimoto et al.
CANCER GENETICS AND CYTOGENETICS (2006)
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
Y. Liu
PROSTATE CANCER AND PROSTATIC DISEASES (2006)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men
CJ Malkin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Share Paper
